X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2420) 2420
Publication (367) 367
Book Review (27) 27
Book Chapter (5) 5
Conference Proceeding (4) 4
Dissertation (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2212) 2212
cetuximab (1913) 1913
index medicus (1720) 1720
oncology (1340) 1340
receptor, epidermal growth factor - metabolism (860) 860
female (845) 845
cancer (743) 743
antibodies, monoclonal, humanized (740) 740
cell line, tumor (717) 717
animals (710) 710
male (667) 667
receptor, epidermal growth factor - antagonists & inhibitors (640) 640
antineoplastic agents - therapeutic use (596) 596
colorectal cancer (588) 588
chemotherapy (568) 568
growth-factor receptor (562) 562
colorectal neoplasms - drug therapy (541) 541
middle aged (535) 535
egfr (533) 533
antibodies, monoclonal - therapeutic use (507) 507
aged (495) 495
antineoplastic agents - pharmacology (488) 488
mice (460) 460
mutation (457) 457
epidermal growth factor (406) 406
adult (398) 398
colorectal neoplasms - pathology (383) 383
antibodies, monoclonal - pharmacology (374) 374
tumors (356) 356
expression (355) 355
colorectal neoplasms - genetics (351) 351
colorectal neoplasms - metabolism (349) 349
antineoplastic combined chemotherapy protocols - therapeutic use (346) 346
treatment outcome (330) 330
care and treatment (324) 324
receptor, epidermal growth factor - genetics (308) 308
therapy (300) 300
metastasis (292) 292
prognosis (289) 289
research (286) 286
monoclonal antibodies (264) 264
1st-line treatment (260) 260
metastatic colorectal-cancer (250) 250
aged, 80 and over (249) 249
mice, nude (242) 242
pharmacology & pharmacy (240) 240
cell proliferation - drug effects (239) 239
antibodies, monoclonal - administration & dosage (238) 238
ras proteins - genetics (236) 236
analysis (235) 235
epidermal growth factor receptor (235) 235
signal transduction (232) 232
article (230) 230
xenograft model antitumor assays (230) 230
panitumumab (225) 225
monoclonal-antibody (219) 219
signal transduction - drug effects (217) 217
proto-oncogene proteins p21 (216) 216
bevacizumab (212) 212
immunohistochemistry (208) 208
genetic aspects (204) 204
proto-oncogene proteins - genetics (203) 203
antineoplastic agents (202) 202
neoplasms (202) 202
head and neck neoplasms - drug therapy (200) 200
colorectal-cancer (198) 198
health aspects (198) 198
carcinoma, squamous cell - metabolism (196) 196
hematology, oncology and palliative medicine (196) 196
biomarkers, tumor - metabolism (195) 195
cancer therapies (195) 195
neoplasm metastasis (192) 192
kras (191) 191
cell biology (189) 189
phosphorylation (189) 189
antimitotic agents (187) 187
apoptosis (186) 186
carcinoma (186) 186
lung-cancer (186) 186
drug resistance, neoplasm (185) 185
disease-free survival (184) 184
cell lung-cancer (183) 183
drug therapy (183) 183
cetuximab - pharmacology (179) 179
squamous-cell carcinoma (179) 179
carcinoma, squamous cell - drug therapy (177) 177
gefitinib (175) 175
medicine & public health (175) 175
digestive system diseases (174) 174
erbb receptors - metabolism (173) 173
head and neck neoplasms - metabolism (172) 172
proteins (172) 172
resistance (170) 170
apoptosis - drug effects (169) 169
carcinoma, squamous cell - pathology (169) 169
cetuximab plus irinotecan (167) 167
receptor, epidermal growth factor - immunology (166) 166
survival (166) 166
breast-cancer (165) 165
squamous cell carcinoma (165) 165
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2379) 2379
Chinese (15) 15
French (11) 11
Japanese (6) 6
German (4) 4
Hungarian (4) 4
Korean (3) 3
Spanish (2) 2
Italian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 03/2013, Volume 8, Issue 3, p. e60317
Aberrant expression of microRNA-146a (miR-146a) has been reported to be involved in the development and progression of various types of cancers. However, its... 
SUPPRESSOR | ONCOGENESIS | RNA | MULTIDISCIPLINARY SCIENCES | CERVICAL-CANCER | INTERFERENCE | MICRORNAS | NF-KAPPA-B | FACTOR RECEPTOR | EXPRESSION | CONTRIBUTES | Lung Neoplasms - drug therapy | Humans | Lung Neoplasms - metabolism | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | MicroRNAs - metabolism | NF-kappa B - metabolism | Receptor, Epidermal Growth Factor - metabolism | Antibodies, Monoclonal, Humanized - pharmacology | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Lung - metabolism | Cetuximab | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung - pathology | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Lung - drug effects | Cell Line, Tumor | Aged | Cell Proliferation - drug effects | MicroRNAs - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Apoptosis | Cell Movement | MicroRNA | Growth | Monoclonal antibodies | Lung cancer, Small cell | Development and progression | Lung cancer, Non-small cell | Health aspects | Cell proliferation | Laboratories | Lung cancer | Oncology | Drug delivery | Kinases | Paraffin | Cancer therapies | Metastases | Signal transduction | Cell growth | Bioindicators | Inhibition | Gefitinib | Sensitizing | NF-κB protein | Phenotypes | Cytokines | Epidermal growth factor receptors | MiRNA | Non-small cell lung carcinoma | siRNA | Breast cancer | Gene expression | Ribonucleic acid--RNA | Patients | Pathology | Signaling | Chemotherapy | Thyroid cancer | MicroRNAs | Medical prognosis | Pancreatic cancer | Cell lines | Biomarkers | Mutation | Cell migration | Cervical cancer | Tumors | Cancer | Ribonucleic acid
Journal Article
British Journal of Cancer, ISSN 0007-0920, 08/2008, Volume 99, Issue 4, pp. 622 - 631
Little is known about the factors that enable the mobilisation of human mesenchymal stem cells (MSC) from the bone marrow into the blood stream and their... 
Angiogenesis | MSC | Pancreas | Lentivirus | VEGF | angiogenesis | BONE-MARROW | VESSEL MATURATION | CANCER | ADHESION | IN-VITRO | ONCOLOGY | pancreas | BLOOD-VESSELS | SMOOTH-MUSCLE-CELLS | TUMOR STROMA | MARROW STROMAL CELLS | lentivirus | ENDOTHELIAL GROWTH-FACTOR | Endothelium, Vascular - cytology | Cell Proliferation | Pancreatic Neoplasms - metabolism | Humans | Pancreatic Neoplasms - blood supply | Actins - metabolism | Spheroids, Cellular - pathology | Endothelium, Vascular - drug effects | Male | Transplantation, Heterologous | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Antibodies, Monoclonal, Humanized | Muscle, Smooth - drug effects | Umbilical Veins - drug effects | Lentivirus - genetics | Antineoplastic Agents - pharmacology | Cetuximab | Umbilical Veins - cytology | Fibroblasts - metabolism | Antibodies, Monoclonal - pharmacology | Pancreatic Neoplasms - pathology | Cells, Cultured | Angiogenesis Inhibitors - pharmacology | Mesenchymal Stromal Cells - metabolism | Epidermal Growth Factor - metabolism | Muscle, Smooth - metabolism | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Cell Movement - drug effects | Platelet-Derived Growth Factor - metabolism | Animals | Cell Differentiation - drug effects | Endothelium, Vascular - metabolism | Mice, Nude | Fibroblasts - drug effects | Epidermal Growth Factor - antagonists & inhibitors | Fibroblasts - cytology | Mice | Neovascularization, Pathologic - metabolism | Benzamides | Muscle, Smooth - cytology | Platelet-Derived Growth Factor - antagonists & inhibitors | Mesenchymal Stem Cell Transplantation | Umbilical Veins - metabolism | Translational Therapeutics
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 8/2013, Volume 62, Issue 8, pp. 1347 - 1357
Cetuximab is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody that prolongs survival in the treatment for head and neck cancer (HNC), but... 
Immunology | Medicine & Public Health | VTX-2337 | Immunotherapy | Oncology | Cancer Research | TLR8 | Head and neck cancer | Cetuximab | ADCC | IMMUNITY | IFN-GAMMA PRODUCTION | MECHANISMS | IMMUNOLOGY | IMIQUIMOD | BLIND | TOLL-LIKE | NK CELLS | ONCOLOGY | CARCINOMA | AGONIST | Tumor Necrosis Factor-alpha - metabolism | Antigens, CD - immunology | Immunoglobulins - immunology | Membrane Glycoproteins - metabolism | Coculture Techniques | Dendritic Cells - immunology | Humans | Antibody-Dependent Cell Cytotoxicity - immunology | Interferon-gamma - metabolism | Head and Neck Neoplasms - metabolism | Antigens, CD - metabolism | Immunoglobulins - metabolism | Toll-Like Receptor 8 - immunology | Receptor, Epidermal Growth Factor - metabolism | Flow Cytometry | Antibodies, Monoclonal, Humanized - pharmacology | Benzazepines - immunology | Tumor Necrosis Factor-alpha - immunology | CD8-Positive T-Lymphocytes - metabolism | Killer Cells, Natural - immunology | Antineoplastic Agents - pharmacology | Interleukin-12 Subunit p40 - immunology | Membrane Glycoproteins - immunology | B7-2 Antigen - immunology | Dendritic Cells - metabolism | Toll-Like Receptor 8 - agonists | Interleukin-12 Subunit p40 - metabolism | Receptor, Epidermal Growth Factor - immunology | Enzyme-Linked Immunosorbent Assay | Antineoplastic Agents - immunology | B7-1 Antigen - immunology | Cells, Cultured | B7-1 Antigen - metabolism | Benzazepines - pharmacology | Head and Neck Neoplasms - pathology | B7-2 Antigen - metabolism | Head and Neck Neoplasms - immunology | Cross-Priming - immunology | Interferon-gamma - immunology | Cell Line, Tumor | Killer Cells, Natural - metabolism | Antibodies, Monoclonal, Humanized - immunology | Antibody-Dependent Cell Cytotoxicity - drug effects | CD8-Positive T-Lymphocytes - immunology | Toll-Like Receptor 8 - metabolism | Index Medicus | Head and Neck Cancer
Journal Article
Cancer Cell, ISSN 1535-6108, 04/2015, Volume 27, Issue 4, pp. 533 - 546
Journal Article
Nature Cell Biology, ISSN 1465-7392, 2014, Volume 16, Issue 3, pp. 268 - 280
Asymmetrical cell division (ACD) maintains the proper number of stem cells to ensure self-renewal. In cancer cells, the deregulation of ACD disrupts the... 
EPITHELIAL-MESENCHYMAL TRANSITION | COLON-CANCER | ACTIVATION | GENE-EXPRESSION | NOTCH | NUMB | SMALL-INTESTINE | BETA-CATENIN | PROTEINS | TRANSCRIPTION FACTOR | CELL BIOLOGY | Adenocarcinoma - pathology | Prognosis | Mitosis | Humans | Gene Expression Regulation, Neoplastic | Drug Resistance, Neoplasm | MicroRNAs - metabolism | Adenocarcinoma - metabolism | Proteolysis | Antibodies, Monoclonal, Humanized - pharmacology | Base Sequence | Colorectal Neoplasms - drug therapy | Female | Transcription, Genetic | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | 3' Untranslated Regions | Cetuximab | Binding Sites | Snail Family Transcription Factors | Colorectal Neoplasms - metabolism | Neoplastic Stem Cells - physiology | Wnt Signaling Pathway | Colorectal Neoplasms - mortality | Transcription Factors - physiology | Transcription Factor 4 | Membrane Proteins - genetics | Kaplan-Meier Estimate | Adenocarcinoma - drug therapy | Nerve Tissue Proteins - genetics | beta Catenin - metabolism | Nerve Tissue Proteins - metabolism | Transcription Factors - metabolism | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Mice, Nude | Cell Line, Tumor | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - metabolism | Mice | Mice, Inbred BALB C | MicroRNAs - genetics | Colorectal Neoplasms - pathology | Adenocarcinoma - mortality | MicroRNA | Oncology, Experimental | Neoplastic processes | Colorectal cancer | Stem cells | Genetic aspects | Research | Identification and classification | Cancer
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2010, Volume 46, Issue 11, pp. 1997 - 2009
Abstract Background Anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC) treatment are only effective in patients with KRAS wild type... 
Hematology, Oncology and Palliative Medicine | PI3K pathway | Predictive markers | BRAF | RAS/MAPK pathway | Cetuximab | Metastatic colorectal cancer | PLUS IRINOTECAN | BEVACIZUMAB | PHASE-III | CHEMOTHERAPY | KRAS MUTATIONS | PANITUMUMAB | GROWTH-FACTOR RECEPTOR | MUTATION STATUS | GENE | ONCOLOGY | BRAF MUTATION | Immunohistochemistry | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | ras Proteins - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Phosphatidylinositol 3-Kinases - metabolism | Neoplasm Proteins - metabolism | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Colorectal Neoplasms - drug therapy | Biomarkers, Tumor - metabolism | Female | Genes, Neoplasm - genetics | Colorectal Neoplasms - metabolism | Proto-Oncogene Proteins B-raf - metabolism | Genes, ras - genetics | Proto-Oncogene Proteins - metabolism | PTEN Phosphohydrolase - metabolism | In Situ Hybridization, Fluorescence | Treatment Outcome | Mutation - genetics | Class I Phosphatidylinositol 3-Kinases | Genes, erbB-2 - genetics | Biomarkers, Tumor - genetics | Antimitotic agents | Cancer patients | Care and treatment | Epidermal growth factor | Patient outcomes | Toluene | Colorectal cancer | Monoclonal antibodies | Metastasis | Antineoplastic agents | Cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2012, Volume 18, Issue 9, pp. 2515 - 2525
Journal Article
Cancer Research, ISSN 0008-5472, 08/2004, Volume 64, Issue 15, pp. 5355 - 5362
Molecular inhibition of epidermal growth factor receptor (EGFR/HER1) signaling is under active investigation as a promising cancer treatment strategy. We... 
PATHWAYS | APOPTOSIS | HEAD | THERAPY | CANCER CELLS | ONCOLOGY | RESISTANCE | TUMOR-CELLS | PROLIFERATION | TARCEVA | BREAST | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Prostatic Neoplasms - metabolism | Apoptosis - drug effects | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Immunoblotting | Male | Transplantation, Heterologous | Head and Neck Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Flow Cytometry | Female | Quinazolines - administration & dosage | Phosphorylation - drug effects | Tumor Cells, Cultured | Cetuximab | Prostatic Neoplasms - drug therapy | Protein-Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | Enzyme Inhibitors - pharmacology | Head and Neck Neoplasms - drug therapy | Cell Division - drug effects | Proto-Oncogene Proteins c-akt | Animals | Carcinoma, Squamous Cell - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Proliferating Cell Nuclear Antigen - metabolism | Mitogen-Activated Protein Kinases - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Cancer Letters, ISSN 0304-3835, 2016, Volume 381, Issue 1, pp. 23 - 30
Highlights • ASCT2 is physically associated with EGFR in a molecular complex. • Cetuximab downregulates ASCT2 via cetuximab-mediated EGFR endocytosis. •... 
Hematology, Oncology and Palliative Medicine | Cetuximab | ASCT2 | HNSCC | EGFR | ROS | Glutathione | SURVIVAL | DICHLOROACETATE DCA | TUMORS | GLUTAMINE UPTAKE | LUNG-CANCER | TRANSPORT | METABOLISM | ONCOLOGY | REDOX REGULATION | EPIDERMAL-GROWTH-FACTOR | RESISTANCE | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Glutathione - metabolism | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Humans | ErbB Receptors - genetics | Glutamine - metabolism | Head and Neck Neoplasms - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Squamous Cell Carcinoma of Head and Neck | Transfection | RNA Interference | Time Factors | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Gefitinib | Protein-Serine-Threonine Kinases - metabolism | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | Down-Regulation | Endocytosis - drug effects | Head and Neck Neoplasms - drug therapy | Protein-Serine-Threonine Kinases - genetics | Amino Acid Transport System ASC - metabolism | Cetuximab - pharmacology | Head and Neck Neoplasms - pathology | Minor Histocompatibility Antigens - metabolism | Carcinoma, Squamous Cell - drug therapy | Signal Transduction - drug effects | Dichloroacetic Acid - pharmacology | Cell Line, Tumor | Head and Neck Neoplasms - genetics | Protein Kinase Inhibitors - pharmacology | Oxidative Stress - drug effects | Quinazolines - pharmacology | Antimitotic agents | Antineoplastic agents | Apoptosis | Phosphorylation | Immunoglobulins | Clinical trials | Radiation therapy | Metastasis | Kinases | Cancer therapies | Studies | Proteins | Hypotheses | Metabolic disorders | Tumors | Cancer | cetuximab | glutamine
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2008, Volume 14, Issue 20, pp. 6456 - 6468
Purpose: It was the aim of our study to establish an extensive panel of non-small cell lung cancer (NSCLC) xenograft models useful for the testing of novel... 
xenograft | NSCLC | erlotinib | mutational analysis | anti-EGFR therapy | cetuximab | biomarker | TARGETED THERAPY | KRAS MUTATIONS | GROWTH-FACTOR RECEPTOR | NUDE-MICE | TUMOR XENOGRAFTS | GEFITINIB | ONCOLOGY | GENE-EXPRESSION | TYROSINE KINASE INHIBITOR | EGFR MUTATIONS | ANTITUMOR-ACTIVITY | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Oligonucleotide Array Sequence Analysis | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Middle Aged | Drug Resistance, Neoplasm | Immunoblotting | Male | Gene Expression Profiling | Adenocarcinoma - metabolism | Biomarkers, Tumor - metabolism | Cetuximab | Disease Models, Animal | Genes, ras - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Etoposide - pharmacology | Mutation - genetics | Adenocarcinoma - drug therapy | Small Cell Lung Carcinoma - pathology | Carcinoma, Squamous Cell - drug therapy | Mice, Nude | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives | Erlotinib Hydrochloride | Paclitaxel - pharmacology | Prognosis | Carcinoma, Squamous Cell - metabolism | Deoxycytidine - pharmacology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Tumor Suppressor Protein p53 - genetics | Small Cell Lung Carcinoma - metabolism | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Vinblastine - analogs & derivatives | Polymerase Chain Reaction | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Radiation-Sensitizing Agents - pharmacology | Tumor Suppressor Protein p53 - metabolism | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Protein Kinase Inhibitors - pharmacology | Vinblastine - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents, Phytogenic - pharmacology
Journal Article
Cancer Letters, ISSN 0304-3835, 2016, Volume 373, Issue 1, pp. 36 - 44
Highlights • Cisplatin downregulates HIF-1α in cisplatin-sensitive ovarian cancer cells. • Inhibition of HIF-1α resensitizes cisplatin-resistant ovarian cancer... 
Hematology, Oncology and Palliative Medicine | Resistance | HIF-1 | Cancer metabolism | Cisplatin | Ovarian cancer | MITOCHONDRIA | HYPOXIA | INHIBITION | THERAPY | ONCOLOGY | GROWTH | ADAPTATION | ANTIBODY CETUXIMAB | EXPRESSION | CARCINOMA | L-Lactate Dehydrogenase - metabolism | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Humans | Ovarian Neoplasms - pathology | Glycolysis - drug effects | Gene Knockdown Techniques | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | Oxidative Phosphorylation - drug effects | Transfection | RNA Interference | Time Factors | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Isoenzymes - metabolism | Proteolysis | Female | Antineoplastic Agents - pharmacology | Ovarian Neoplasms - metabolism | Ovarian Neoplasms - drug therapy | Hypoxia-Inducible Factor 1, alpha Subunit - genetics | Isoenzymes - genetics | Down-Regulation | Mitochondria - metabolism | Cisplatin - pharmacology | Mitochondria - drug effects | Drug Resistance, Neoplasm - genetics | L-Lactate Dehydrogenase - genetics | Cell Line, Tumor | Oxidative Stress - drug effects | Antimitotic agents | Physiological aspects | Antineoplastic agents | Cancer cells | Prevention | Glucose metabolism | Enzymes | Chemotherapy | Cell death | Cancer | Conflicts of interest | Cell growth | Breast cancer | Kinases | Cancer therapies | cancer metabolism | ovarian cancer | resistance
Journal Article